3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
4
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Pancreatic Neoplasms
34
Carcinoma, Non-Small-Cell Lung
15
Breast Neoplasms
13
Neoplasm Metastasis
9
Triple Negative Breast Neoplasms
6
Neoplasms
5
Sarcoma
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Hodgkin Disease
3
Carcinoma, Squamous Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Multiple Myeloma
2
Melanoma
2
Lymphoma
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Pancreatic Ductal
2
Carcinoma
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Spinal Cord Compression
1
Solid Tumor
1
Interventions
Dexamethasone
29
Cyclophosphamide
21
Rituximab
17
Cytarabine
16
Bortezomib
13
Gemcitabine
12
fludarabine
11
Methotrexate
11
Lenalidomide
10
Filgrastim
10
Vincristine
9
Etoposide
9
pomalidomide
8
pembrolizumab
8
Paclitaxel
8
Azacitidine
8
venetoclax
7
carfilzomib
7
Doxorubicin
7
Docetaxel
7
Cyclosporine
7
Calcium Dobesilate
7
Antilymphocyte Serum
7
fludarabine phosphate
6
Topotecan
6
Temozolomide
6
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
Mitoxantrone
6
daratumumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Recurrence
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02075021
2018-10-15
rev/abraxane
NYU Langone Health
Phase 1/2
Terminated
3 enrolled
3 charts